Objective:

To report the FDA approval of YUVEZZI™, a dual-agent eye drop for treating presbyopia in adults.

Key Findings:

• YUVEZZI demonstrated superiority over its individual components in BRIO I.
• In BRIO II, it achieved significant improvements in near visual acuity for up to eight hours.
• Safety study included over 72,000 treatment days with no serious adverse events reported.

Interpretation:

The approval of YUVEZZI represents a significant advancement in non-invasive options for managing presbyopia, addressing patient needs for convenience and flexibility.

Limitations:

• Long-term effects beyond the study duration are not yet known.
• The trials primarily focused on short-term efficacy and safety.

Conclusion:

YUVEZZI's dual-mechanism approach and once-daily dosing may provide a valuable alternative for patients seeking pharmacologic correction of near vision.